Literature DB >> 22189032

Changes of the transverse diameter and volume and dosimetry before the 25th fraction during the course of intensity-modulated radiation therapy (IMRT) for patients with nasopharyngeal carcinoma.

Haihua Yang1, Wei Hu, Weijun Ding, Guoping Shan, Wei Wang, Changhui Yu, Biyun Wang, Minghai Shao, Jianhua Wang, Weifang Yang.   

Abstract

To quantify changes of the transverse diameter and volume and dosimetry, and to illustrate the inferiority of non-replanning during intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma (NPC) patients. Fifty-three NPC patients who received IMRT in 33 fractions were enrolled in this prospective trial. Before the 25th fraction, a new simulation computed tomography (CT) scan was acquired for all patients. The dose-volume histograms of the phantom plan were compared with the initial plan. Significant reduction of the transverse diameter of the nasopharyngeal, the neck, and 2 parotid glands volume was observed on second CT compared with the first CT (mean reduction 7.48 ± 4.45 mm, 6.80 ± 15.14 mm, 5.70 ± 6.26 mL, and 5.04 ± 5.85 mL, respectively; p < 0.01). The maximum dose and V-40 of the spinal cord, mean dose, and V30 of the left and right parotid, and V-50 of the brain stem were increased significantly in the phantom plan compared with the initial plan (mean increase 4.75 ± 5.55 Gy, 7.18 ± 10.07%, 4.51 ± 8.55 Gy, 6.59 ± 17.82%, 5.33 ± 8.55 Gy, 11.68 ± 17.11% and 1.48 ± 3.67%, respectively; p < 0.01). On the basis of dose constraint criterion in the RTOG0225 protocol, the dose of the normal critical structures for 52.83% (28/53) of the phantom plans were out of limit compared with 1.89% (1/53) of the initial plans (p < 0.0001). Because of the significant change in anatomy and dose before the 25th fraction during IMRT, replanning should be necessary during IMRT with NPC.
Copyright © 2012 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22189032     DOI: 10.1016/j.meddos.2011.08.003

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  6 in total

1.  Is it necessary to repeat CT imaging and replanning during the course of intensity-modulated radiation therapy for locoregionally advanced nasopharyngeal carcinoma?

Authors:  Chuanben Chen; Xiang Lin; Jianji Pan; Zhaodong Fei; Lisha Chen; Penggang Bai
Journal:  Jpn J Radiol       Date:  2013-06-09       Impact factor: 2.374

2.  The tumor shape changes of nasopharyngeal cancer during chemoradiotherapy: the estimated margin to cover the geometrical variation.

Authors:  Wenyong Tan; Jianzeng Ye; Ruilian Xu; Xianming Li; Wan He; Xiaohong Wang; Yanping Li; Desheng Hu
Journal:  Quant Imaging Med Surg       Date:  2016-04

3.  Rules of parotid gland dose variations and shift during intensity modulated radiation therapy for nasopharyngeal carcinoma.

Authors:  Wei Wang; Haihua Yang; Yucheng Mi; Wei Hu; Weijun Ding; Youyou Xie; Yujie Cai; Xiaofeng Chen
Journal:  Radiat Oncol       Date:  2015-01-08       Impact factor: 3.481

4.  A longitudinal evaluation of early anatomical changes of parotid gland in intensity modulated radiotherapy of nasopharyngeal carcinoma patients with parapharyngeal space involvement.

Authors:  Yingting Zhang; Chengguang Lin; Jianhua Wu; Xiaobo Jiang; Shara W Y Lee; Shing-Yau Tam; Vincent W C Wu
Journal:  J Med Radiat Sci       Date:  2017-03-04

5.  Analytical approach for determining beam profiles in water phantom of symmetric and asymmetric fields of wedged, blocked, and open photon beams.

Authors:  Mohamad Javad Tahmasebi Birgani; Nahid Chegeni; Shole Arvandi; Sasan Razmjoo Ghalaee; Mansoor Zabihzadeh; Davood Khezerloo
Journal:  J Appl Clin Med Phys       Date:  2013-11-04       Impact factor: 2.102

6.  High HLA-F Expression Is a Poor Prognosis Factor in Patients with Nasopharyngeal Carcinoma.

Authors:  Bo Wu; Haihua Yang; Shenpeng Ying; Hongsheng Lu; Wei Wang; Jiaming Lv; Huacai Xiong; Wei Hu
Journal:  Anal Cell Pathol (Amst)       Date:  2018-10-30       Impact factor: 2.916

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.